Jubilant Pharmova reported its Q4 FY26 results with revenue growth remaining strong on a year-on-year basis, while profitability declined due to higher expenses and exceptional items.
The company posted consolidated revenue from operations of ₹2,290 crore in Q4 FY26, compared to ₹1,926.8 crore in the corresponding quarter last year, registering a growth of 18.8% YoY.
Total income stood at ₹2,313.7 crore versus ₹1,940.7 crore in Q4 FY25, up 19.2% YoY.
However, profit after tax declined 21.2% YoY to ₹119.3 crore in the March quarter, compared with ₹151.3 crore reported in the same period last year.
Profit before tax came in at ₹176 crore against ₹206 crore in Q4 FY25, marking a decline of 14.6% YoY.
Employee benefit expenses increased sharply to ₹766.9 crore from ₹590.5 crore in the year-ago quarter, while other expenses rose to ₹470.5 crore from ₹356.7 crore.
Finance costs also edged higher to ₹56.5 crore versus ₹52.7 crore on a YoY basis.
Depreciation, amortisation and impairment expenses increased to ₹116.8 crore compared with ₹95.2 crore in the corresponding quarter last year.
For the full FY26 period, the company reported revenue from operations of ₹8,279.6 crore, up 14.4% from ₹7,234.5 crore in FY25.
Annual profit after tax fell sharply to ₹397.5 crore from ₹836.3 crore in FY25. The company’s total expenses for FY26 rose to ₹7,672 crore compared with ₹6,669.7 crore in the previous financial year.